.: ORİJİNAL ARAŞTIRMA
Primer Akciğer Kanserlerinde Lenfanjitis Karsinomatozanın Evre ve Sağkalım Üzerine Etkisi
The Effect of Lymphangitis Carcinomatosa on the Stage, and Survival in the Primary Lung Cancers
Turkiye Klinikleri J Med Sci. 2019;39(1):48-55
doi: 10.5336/medsci.2018-62985
Makale Dili: TR
Tam Metin
ÖZET
Amaç: Primer akciğer kanserlerinde lenfanjitis karsinomatoza (LK) varlığının evre ve sağkalım üzerine etkisini araştırmak. Gereç ve Yöntemler: Çalışmaya 2014-2016 yılları arasında primer akciğer kanser tanısı almış olgular dahil edildi. Olgular tanı aşamasında radyolojik olarak LK tespit edilen ve LK tespit edilmeyenler olarak iki gruba ayrıldı. İki gruptaki olguların demografik, klinik, radyolojik ve sağkalım özellikleri kayıt edildi. Her iki grubun verileri birbirleri ile karşılaştırıldı. Gruplara ait veriler Ki-kare ve Mann-Whitney U testleri ile değerlendirildi. Tüm testlerde p<0,05 istatistiksel anlamlı kabul edildi. Bulgular: Çalışmaya 264'ü (%82,2) erkek, 55'i (%17,8) kadın, yaş ortalaması 61,9±9,6 yıl olan toplam 319 olgu alındı. Ortalama sigara içme öyküsü 39,1±17,3 paket-yılı idi. Olguların 28'inde (%8,8) LK var iken, 291'inde (%91,2) LK yoktu. Olguların tümör histopatolojileri incelendiğinde her iki grupta da en sık görülen tümör cinsi skuamöz hücreli kanserdi. Lenfanjitis karsinomatoza tespit edilen ve edilmeyen olguların özellikleri (Histopatolojik tanı, evre, cerrahi/onkolojik tedavi özellikleri, sigara öyküsü, yaş, cinsiyet özellikleri) arasında fark bulunmadı. LK tespit edilen akciğer kanserlerinin ortanca genel sağkalım süreleri (11 ay) LK tespit edilmeyen özellikle evre 3B (12 ay) kanserler ile çok benzerdi (p=0,524). Sonuç: Varlığında sağkalım ve prognozun kötü etkilendiği bilinen LK, akciğer kanserlerinde sağkalımı etkilemektedir bu nedenle akciğer kanser evrelemelerinde dikkate alınmalıdır.
Anahtar Kelimeler: Akciğer kanseri; lenfanjitis karsinomatoza; sağkalım
Amaç: Primer akciğer kanserlerinde lenfanjitis karsinomatoza (LK) varlığının evre ve sağkalım üzerine etkisini araştırmak. Gereç ve Yöntemler: Çalışmaya 2014-2016 yılları arasında primer akciğer kanser tanısı almış olgular dahil edildi. Olgular tanı aşamasında radyolojik olarak LK tespit edilen ve LK tespit edilmeyenler olarak iki gruba ayrıldı. İki gruptaki olguların demografik, klinik, radyolojik ve sağkalım özellikleri kayıt edildi. Her iki grubun verileri birbirleri ile karşılaştırıldı. Gruplara ait veriler Ki-kare ve Mann-Whitney U testleri ile değerlendirildi. Tüm testlerde p<0,05 istatistiksel anlamlı kabul edildi. Bulgular: Çalışmaya 264'ü (%82,2) erkek, 55'i (%17,8) kadın, yaş ortalaması 61,9±9,6 yıl olan toplam 319 olgu alındı. Ortalama sigara içme öyküsü 39,1±17,3 paket-yılı idi. Olguların 28'inde (%8,8) LK var iken, 291'inde (%91,2) LK yoktu. Olguların tümör histopatolojileri incelendiğinde her iki grupta da en sık görülen tümör cinsi skuamöz hücreli kanserdi. Lenfanjitis karsinomatoza tespit edilen ve edilmeyen olguların özellikleri (Histopatolojik tanı, evre, cerrahi/onkolojik tedavi özellikleri, sigara öyküsü, yaş, cinsiyet özellikleri) arasında fark bulunmadı. LK tespit edilen akciğer kanserlerinin ortanca genel sağkalım süreleri (11 ay) LK tespit edilmeyen özellikle evre 3B (12 ay) kanserler ile çok benzerdi (p=0,524). Sonuç: Varlığında sağkalım ve prognozun kötü etkilendiği bilinen LK, akciğer kanserlerinde sağkalımı etkilemektedir bu nedenle akciğer kanser evrelemelerinde dikkate alınmalıdır.
Anahtar Kelimeler: Akciğer kanseri; lenfanjitis karsinomatoza; sağkalım
ABSTRACT
Objective: To investigate the effect of lymphangitis carcinomatosa on the stage, and survival in the primary lung cancers. Material and Methods: Patients diagnosed with primary lung cancer between 2014-2016 were included in the study. The patients were divided into two groups who were radiologically detected as having lymphangitis carcinomatosa, and who were detected with no lymphangitis carcinomatosa at diagnosis. The demographic, clinical, radiologic, and survival data of the patients were recorded in both groups. The data of both grups were compared. The data of the groups were evaluated using the Chi-square and Mann-Whitney U test and p<0.05 was considered as significant. Results: A total of 319 patients were included in the study. 264 (82.2%) of the cases were male and 55 (17.8%) were female. The mean age of the patients was 61.9±9.6. The average smoking history was 39.1±17.3 pack-years. 28 patients (8.8%) were diagnosed with LC, and 291 (91.2%) were not detected LC. When tumor histopathology of the cases were examined, the most common tumor type squamous cell carcinoma was found in both groups. No difference was detected in the characteristics of the patients diagnosed with LC, and of the patients diagnosed with no LC (Histopathologic diagnosis, stage, surgical/oncologic treatment features, history of smoking, age, and sex). The median general survival times in lung cancers detected with LC (11 months) were very similar particularly with the stage 3B (12 months) cancers with no LC (p=0.524). Conclusion: Lymphangitis carcinomatosa which is known to poorly affect the survival and prognosis, affects the survival in lung cancers. Therefore, LC must be considered in the staging of lung cancer.
Keywords: Lung neoplasms; lymphangitis; survival
Objective: To investigate the effect of lymphangitis carcinomatosa on the stage, and survival in the primary lung cancers. Material and Methods: Patients diagnosed with primary lung cancer between 2014-2016 were included in the study. The patients were divided into two groups who were radiologically detected as having lymphangitis carcinomatosa, and who were detected with no lymphangitis carcinomatosa at diagnosis. The demographic, clinical, radiologic, and survival data of the patients were recorded in both groups. The data of both grups were compared. The data of the groups were evaluated using the Chi-square and Mann-Whitney U test and p<0.05 was considered as significant. Results: A total of 319 patients were included in the study. 264 (82.2%) of the cases were male and 55 (17.8%) were female. The mean age of the patients was 61.9±9.6. The average smoking history was 39.1±17.3 pack-years. 28 patients (8.8%) were diagnosed with LC, and 291 (91.2%) were not detected LC. When tumor histopathology of the cases were examined, the most common tumor type squamous cell carcinoma was found in both groups. No difference was detected in the characteristics of the patients diagnosed with LC, and of the patients diagnosed with no LC (Histopathologic diagnosis, stage, surgical/oncologic treatment features, history of smoking, age, and sex). The median general survival times in lung cancers detected with LC (11 months) were very similar particularly with the stage 3B (12 months) cancers with no LC (p=0.524). Conclusion: Lymphangitis carcinomatosa which is known to poorly affect the survival and prognosis, affects the survival in lung cancers. Therefore, LC must be considered in the staging of lung cancer.
Keywords: Lung neoplasms; lymphangitis; survival
REFERANSLAR:
- Soares FA, Pinto AP, Landell GA, de Oliveira JA. Pulmonary tumor embolism to arterial vessels and carcinomatous lymphangitis. A comparative clinicopathological study. Arch Pathol Lab Med. 1993;117(8):827-31. [PubMed]
- Natsume M, Honda T, Haruyama T, Ishihara M, Fukasawa Y, Sakamoto T, et al. A case of lung adenocarcinoma with marked improvement of pulmonary lymphangitic carcinomatosis by adding bevacizumab to cisplatin and pemetrexed. Case Rep Oncol. 2017;10(3):1065-9. [Crossref] [PubMed] [PMC]
- Shimizu K, Kubo H, Yamaguchi K, Kawashima K, Ueda Y, Matsuo K, et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 2004;95(4):328-33. [Crossref] [PubMed]
- Bruce DM, Heys SD, Eremin O. Lymphangitis carcinomatosa: a literature review. J R Coll Surg Edinb. 1996;41(1):7-13. [PubMed]
- Munk PL, Müller NL, Miller RR, Ostrow DN. Pulmonary lymphangitic carcinomatosis: CT and pathologic findings. Radiology. 1988;166 (3):705-9. [Crossref] [PubMed]
- Carter BW, Godoy MC, Wu CC, Erasmus JJ, Truong MT. Current controversies in lung cancer staging. J Thorac Imaging. 2016;31(4): 201-14. [Crossref] [PubMed]
- Kay FU, Kandathil A, Batra K, Saboo SS, Abbara S, Rajiah P. Revisions to the tumor, node, metastasis staging of lung cancer (8th edition): rationale, radiologic findings and clinical implications. World J Radiol. 2017;9(6): 269-79. [Crossref] [PubMed] [PMC]
- Nair A, Klusmann MJ, Jogeesvaran KH, Grubnic S, Green SJ, Vlahos I. Revisions to the TNM staging of non-small cell lung cancer: rationale, clinicoradiologic implications, and persistent limitations. Radiographics. 2011;31(1): 215-38. [Crossref] [PubMed]
- Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-14. [Crossref] [PubMed]
- Thomas A, Lenox R. Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult. CMAJ. 2008;179(4):338-40. [Crossref] [PubMed] [PMC]
- Pasławski M, Krzyzanowski K, Złomaniec J. Lymphangitis carcinomatosa in thin section computed tomography. Ann Univ Mariae Curie Sklodowska Med. 2004;59(1):1-5. [PubMed]
- Köksal D, Akduman S. [From the 7th TNM staging to the 8th in lung cancer]. Tuberk Toraks. 2014;62(1):79-84. [Crossref] [PubMed]
- Sakuma M, Fukui S, Nakamura M, Takahashi T, Kitamukai O, Yazu T, et al. Cancer and pulmonary embolism: thrombotic embolism, tumor embolism, and tumor invasion into a large vein. Circ J. 2006;70(6):744-9. [Cross - ref] [PubMed]
- Takahashi M. [Lymphangitis carcinomatosa]. Ryoikibetsu Shokogun Shirizu. 1994;(4):2068. [PubMed]
- Otsuka I, Ono I, Akamatsu H, Sunamori M, Aso T. Pulmonary metastasis from endometrial carcinoma. Int J Gynecol Cancer. 2002;12(2):208-13. [Crossref] [PubMed]
- Guddati AK, Marak CP. Pulmonary lymphangitic carcinomatosis due to renal cell carcinoma. Case Rep Oncol. 2012;5(2):246-52. [Crossref] [PubMed] [PMC]
- Lindqvist C, Lepäntalo M, Jungell P. Lymphangitis carcinomatosa of the lungs. An unusual complication of oral cancer. Br J Oral Maxillofac Surg. 1988;26(3):228-31. [Cross ref]
- Dennstedt FE, Greenberg SD, Kim HS, Weilbaecher DG, Bloom K. Pulmonary lymphangitic carcinomatosis from occult stomach carcinoma in young adults: an unusual cause of dyspnea. Chest. 1983;84(6):787-8. [Cross ref] [PubMed]
- Kerr VE, Cadman E. Pulmonary metastases in ovarian cancer. Analysis of 357 patients. Cancer. 1985;56(5):1209-13. [Crossref]
- Yang SP, Lin CC. Lymphangitic carcinomatosis of the lungs. The clinical significance of its roentgenologic classification. Chest. 1972; 62(2):179-87. [Crossref] [PubMed]
- Cömert SŞ, Doğan C, Çağlayan B, Fidan A, Parmaksız ET, Salepçi B. [The features of lymphangitis carcinomatosa cases]. İzmir Göğüs Hastanesi Dergisi. 2013;27(3):173 80.
- Ishida H, Yokota K, Suzuki Y, Endo E, Ogasawara H, Kosaka S, et al. [A rare case of lymphangitis carcinomatosa of the lung due to primary pulmonary adenocarcinoma with intestinal differentiation successfully treated with chemotherapy]. Gan To Kagaku Ryoho. 2015;42(3):371-4. [PubMed]
- Hojo K, Kumasaka Y, Nishiyama S, Higashihara T, Oku Y, Okada M, et al. [A case of adenocarcinoma of lung cancer with multiple brain metastasis and lymphangitis carcinomatosa responding well to chemotherapy with carboplatin, etoposide and ifosfamide]. Gan To Kagaku Ryoho. 1992;19(14):2403-6. [PubMed]
- Yorita K, Tsuji K, Takano Y, Kuroda N, Sakamoto K, Arii K, et al. Acantholytic squamous cell carcinoma of the lung with marked lymphogenous metastases and high titers of myeloperoxidase-antineutrophil cytoplasmic antibodies: a case report. BMC Cancer. 2018;18(1):300. [Crossref] [PubMed] [PMC]
- Park HS, Lee S. Acantholytic squamous cell carcinoma of the lung showing significant signet ring cell component. Histopathology. 2016;68(3):463-5. [Crossref] [PubMed]
- Choi SE, Park HS. Pulmonary acantholytic squamous cell carcinoma with focal signet ring cell morphology mimicking malignant mesothelioma on fine needle aspiration cytology: a case report. Cytopathology. 2016;27(2):131-3. [Crossref] [PubMed]
- Banerjee SS, Eyden BP, Wells S, McWilliam LJ, Harris M. Pseudoangiosarcomatous carcinoma: a clinicopathological study of seven cases. Histopathology. 1992;21(1):13-23. [Crossref] [PubMed]
- Nappi O, Swanson PE, Wick MR. Pseudovascular adenoid squamous cell carcinoma of the lung: clinicopathologic study of three cases and comparison with true pleuropulmonary angiosarcoma. Hum Pathol. 1994;25(4):373-8. [Crossref]
- Smith AR, Raab SS, Landreneau RJ, Silverman JF. Fine-needle aspiration cytologic features of pseudovascular adenoid squamouscell carcinoma of the lung. Diagn Cytopathol. 1999;21(4):265-70. [Crossref]
- Kong M, Ren X, You Q, Yao H, Teng X. Pseudoangiosarcomatous squamous cell carcinoma of the lung. J Int Med Res. 2011; 39(4):1546-54. [Crossref] [PubMed]
- Gupta PR, Joshi N, Meena RC, Ali M. Asymptomatic lymphangitis carcinomatosis due to squamous cell lung carcinoma. Indian J Chest Dis Allied Sci. 2005;47(2):121-3. [PubMed]
- Ikezoe J, Godwin JD, Hunt KJ, Marglin SI. Pulmonary lymphangitic carcinomatosis: chronicity of radiographic findings in long-term survivors. AJR Am J Roentgenol. 1995;165(1): 49-52. [Crossref] [PubMed]
- Smalley AV, Lefante J, Bartolucci A, Carpenter J, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3(2):209-20. [Crossref] [PubMed]
- Ooi H, Chen CY, Hsiao YC, Huang WS, Hsieh BT. Fluorodeoxyglucose uptake in advanced non-small cell lung cancer with and without pulmonary lymphangitic carcinomatosis. Anticancer Res. 2016;36(8):4313-20. [PubMed]
- Suzuki E, Tanahashi M, Yukiue H, Yoshii N, Shitara M, Fujino T, et al. [A patient with lung adenocarcinoma, lymphangitis carcinomatosa, and multiple bone metastases who achieved long-term survival after successful treatment with carboplatin, paclitaxel, and bevacizumab]. Gan To Kagaku Ryoho. 2016;43(5):617-20. [PubMed]
- Fujita J, Yamagishi Y, Kubo A, Takigawa K, Yamaji Y, Takahara J. Respiratory failure due to pulmonary lymphangitis carcinomatosis. Chest. 1993;103(8):967-8. [Crossref] [PubMed]
- Abe Y, Kurita S, Ohkubo Y, Usui H, Hashizume T, Nakamura M, et al. A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res. 2002;22(6B):3485-8. [PubMed]
- Akiyama Y, Kondo H, Shirono R, Fujii Y. A case of lung adenocarcinoma associated with remarkably high levels of CA 19-9 and lymphangitis carcinomatosa. Gan To Kagaku Ryoho. 1997;24(1):93-6. [PubMed]
- Detterbeck FC, Boffa DJ, Tanoue LT, Wilson LD. Details and difficulties regarding the new lung cancer staging system. Chest. 2010; 137(5):1172-80. [Crossref] [PubMed]
.: İşlem Listesi